Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Farnier

Showing results (71-80 of 144) with videos related to

Pageof 15
Sort By:
Atherosclerosis Plus|January 16, 2023
Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemiaJean Ferrières, Michel Farnier, Eric Bruckert, et al.
Archives of Cardiovascular Diseases|December 9, 2008
A randomised trial of three counselling strategies for lifestyle changes in patients with hypercholesterolemia treated with ezetimibe on top of statin therapy (TWICE)Philippe Gabriel Steg, Jean-Claude Verdier, François Carré, et al.
Atherosclerosis|December 7, 2015
Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trialMichel Farnier, Peter Jones, Randall Severance, et al.
European Heart Journal. Acute Cardiovascular Care|May 5, 2020
An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goalsCamille Buonvino, Romain Chopard, Benoît Guillon, et al.
Cardiovascular Therapeutics|July 15, 2010
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapyHelena Vaverkova, Michel Farnier, Maurizio Averna, et al.
Clinical Biochemistry|February 26, 2011
Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary diseaseHelena Vaverkova, Michel Farnier, Maurizio Averna, et al.
Atherosclerosis|October 9, 2018
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY programMichel Farnier, G Kees Hovingh, Gisle Langslet, et al.
European Heart Journal. Case Reports|October 30, 2020
A case report of an acute coronary syndrome in a 10-year-old boy with homozygous familial hypercholesterolaemiaThibault Leclercq, Sylvie Falcon-Eicher, Michel Farnier, et al.
Journal of Clinical Lipidology|October 6, 2018
Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemiaG Kees Hovingh, John R Guyton, Gisle Langslet, et al.
Diabetes & Vascular Disease Research|May 13, 2011
Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetesJohn R Guyton, D John Betteridge, Michel Farnier, et al.
Pageof 15

Showing results (71-80 of 144) with videos related to

Sort By:
Pageof 15
Atherosclerosis Plus|January 16, 2023
Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemiaJean Ferrières, Michel Farnier, Eric Bruckert, et al.
Archives of Cardiovascular Diseases|December 9, 2008
A randomised trial of three counselling strategies for lifestyle changes in patients with hypercholesterolemia treated with ezetimibe on top of statin therapy (TWICE)Philippe Gabriel Steg, Jean-Claude Verdier, François Carré, et al.
Atherosclerosis|December 7, 2015
Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trialMichel Farnier, Peter Jones, Randall Severance, et al.
European Heart Journal. Acute Cardiovascular Care|May 5, 2020
An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goalsCamille Buonvino, Romain Chopard, Benoît Guillon, et al.
Cardiovascular Therapeutics|July 15, 2010
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapyHelena Vaverkova, Michel Farnier, Maurizio Averna, et al.
Clinical Biochemistry|February 26, 2011
Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary diseaseHelena Vaverkova, Michel Farnier, Maurizio Averna, et al.
Atherosclerosis|October 9, 2018
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY programMichel Farnier, G Kees Hovingh, Gisle Langslet, et al.
European Heart Journal. Case Reports|October 30, 2020
A case report of an acute coronary syndrome in a 10-year-old boy with homozygous familial hypercholesterolaemiaThibault Leclercq, Sylvie Falcon-Eicher, Michel Farnier, et al.
Journal of Clinical Lipidology|October 6, 2018
Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemiaG Kees Hovingh, John R Guyton, Gisle Langslet, et al.
Diabetes & Vascular Disease Research|May 13, 2011
Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetesJohn R Guyton, D John Betteridge, Michel Farnier, et al.
Pageof 15